In women without a BRCA1/2 mutation, Portschy et al. [7] showed a less than 1 % 20-year survival benefit due to CPM for patients with stage I breast cancer, with an even smaller benefit for patients with stage II breast cancer. This evidence concerns the gene BRCA1 and breast carcinoma.